Nanoscope Therapeutics

Nanoscope operates at the intersection of biotechnology, ophthalmology, gene therapy, and optogenetics, with a focused strategy around restoring vision in advanced retinal disease. Its lead asset, MCO-010, uses Multi-Characteristic Opsin in a one-time intravitreal gene-therapy approach intended to restore visual function in patients with severe retinitis pigmentosa. MCO-020 extends the platform toward geographic atrophy in advanced age-related macular degeneration through laser-guided, non-viral intravitreal delivery. This gives Nanoscope a broader disease-agnostic thesis than a single-indication ophthalmology program, while its ambient light-activated approach is designed to re-sensitize retinal tissue without perturbing intact circuitry. The company’s market position is strengthened by regulatory progress: MOGENRY’s U.S. Biologics License Application was accepted on Sep 9, 2026, and MCO-010 received orphan-drug designations in Japan and Saudi Arabia during 2026. The main differentiators visible today are platform breadth, a one-time administration model, and late-stage regulatory and supply-chain preparation.

Nanoscope’s trajectory shows a small, grant-supported biotechnology company advancing toward late-stage commercialization. The company raised $3.5 million across three recorded rounds: a $2 million grant on Jun 20, 2020, an undisclosed Series A on Jul 20, 2020, and a $1.5 million National Institutes of Health grant on Sep 14, 2021. Its employee range remains 11–50, but hiring and executive appointments indicate increasing operational complexity. Michael Marquez became CFO in 2022, Samarendra Mohanty and Sulagna Bhattacharya provide founding leadership, and additions in clinical, regulatory, quality, research, and market access expanded the organization through 2025. The major inflection point came in 2026, when Nanoscope moved beyond clinical evidence generation toward regulatory review and commercial readiness. The Sep 9, 2026 acceptance of the MOGENRY Biologics License Application, long-term MCO-010 data presented in September, and expanded Catalent and McKesson-related commercialization arrangements all support that shift. The trajectory remains execution-sensitive: public funding visibility is limited, the Series A amount is undisclosed, and product commercialization depends on regulatory approval. Nonetheless, the sequence of regulatory, manufacturing, distribution, and market-access actions represents a material evolution from early platform development.